|

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

RECRUITINGSponsored by New Valley University
Actively Recruiting
SponsorNew Valley University
Started2025-12-01
Est. completion2025-12-30
Eligibility
Age40 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06067399

Summary

Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.

Eligibility

Age: 40 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)

Exclusion Criteria:

1. Patients diagnosed to have type 1 diabetes.
2. Patients are diagnosed to have secondary diabetes.
3. Clinical states associated with increased RDW:

   * Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.
   * After blood transfusions
   * Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.

Conditions2

DiabetesType 2 Diabetes

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.